Edition:
India

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

36.69USD
20 Sep 2019
Change (% chg)

$0.18 (+0.49%)
Prev Close
$36.51
Open
$37.00
Day's High
$37.25
Day's Low
$36.48
Volume
21,851,016
Avg. Vol
6,735,894
52-wk High
$46.46
52-wk Low
$33.97

Latest Key Developments (Source: Significant Developments)

Merck KGaA: Positive EU Opinion On Avelumab For Renal Cell Cancer
Friday, 20 Sep 2019 

Sept 20 (Reuters) - Merck KGaA ::THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OF THE EUROPEAN MEDICINES AGENCY (EMA) ADOPTED A POSITIVE OPINION RECOMMENDING APPROVAL OF BAVENCIO® (AVELUMAB) IN COMBINATION WITH AXITINIB FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC).OPINION WAS BASED ON POSITIVE FINDINGS FROM THE PHASE III JAVELIN RENAL 101 STUDY.  Full Article

Pfizer's Director Scott Gottlieb Reports Open Market Purchase Of 3,000 Shares
Monday, 26 Aug 2019 

Aug 26 (Reuters) - Pfizer Inc ::PFIZER INC'S DIRECTOR SCOTT GOTTLIEB REPORTS OPEN MARKET PURCHASE OF 3,000 SHARES AT PRICE OF $34.72 PER SHARE ON AUG 23 - SEC FILING.  Full Article

Pfizer Says Upjohn Unit Has No Opioid Liabilities Which Will Transfer To New Company
Monday, 29 Jul 2019 

July 29 (Reuters) - Mylan NV ::PFIZER SAYS MANUFACTURING SUPPLY ISSUES CONTINUE TO AFFECT STERILE INJECTABLES BUSINESS; EXPECTS SIGNIFICANT IMPROVEMENT BY END OF 2019 - CONF. CALL.PFIZER SAYS TARGETING A U.S. REGULATORY SUBMISSION IN LATE Q4, 2019 OR EARLY 2020 FOR TANEZUMAB - CONF. CALL.PFIZER CEO SAYS CANNOT SUPPORT SENATE BILL ON DRUG PRICING AS IT IS WRITTEN ALTHOUGH THERE ARE SOME POSITIVES - CONF. CALL.PFIZER SAYS UPJOHN HAS NO OPIOID LIABILITIES WHICH WILL TRANSFER TO NEW COMPANY- CONF. CALL.  Full Article

Pfizer Says Qtrly Worldwide Ibrance Revenue $1.26 Bln
Monday, 29 Jul 2019 

July 29 (Reuters) - Pfizer Inc ::PFIZER INC SAYS PREVNAR 13/PREVNAR 13 REVENUE $1.18 BILLION VERSUS $1.25 BILLION LAST YEAR.PFIZER INC SAYS QTRLY WORLDWIDE TOTAL LYRICA REVENUE $1.18 BILLION VERSUS $1.22 BILLION LAST YEAR.PFIZER INC SAYS QTRLY WORLDWIDE IBRANCE REVENUE $1.26 BILLION VERSUS $1.03 BILLION REPORTED LAST YEAR.  Full Article

Pfizer Nears Deal To Combine Off-Patent Drug Business With Mylan - WSJ
Saturday, 27 Jul 2019 

July 27 (Reuters) - :PFIZER NEARS DEAL TO COMBINE OFF-PATENT DRUG BUSINESS WITH MYLAN - WSJ.PFIZER & MYLAN DISCUSSED STOCK DEAL IN WHICH MYLAN SHAREHOLDERS WOULD OWN LITTLE MORE THAN 40% OF NEW ENTITY & PFIZER SHAREHOLDERS THE REMAINDER - WSJ.PFIZER WOULD RECEIVE ABOUT $12 BILLION IN PROCEEDS FROM A NEW SALE OF DEBT- WSJ.  Full Article

FDA Approves Boxed Warning About Increased Risk Of Blood Clots & Death With Higher Dose Of Xeljanz, Xeljanz XR
Friday, 26 Jul 2019 

July 26 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES BOXED WARNING ABOUT INCREASED RISK OF BLOOD CLOTS AND DEATH WITH HIGHER DOSE OF ARTHRITIS AND ULCERATIVE COLITIS MEDICINE TOFACITINIB (XELJANZ, XELJANZ XR).U.S. FDA SAYS APPROVED USE OF TOFACITINIB FOR ULCERATIVE COLITIS WILL BE LIMITED TO CERTAIN PATIENTS WHO ARE NOT TREATED EFFECTIVELY.U.S. FDA - APPROVED USE OF TOFACITINIB FOR ULCERATIVE COLITIS TO BE LIMITED TO CERTAIN PATIENTS HAVING SEVERE SIDE EFFECTS WITH CERTAIN OTHER MEDICINES.U.S. FDA SAYS APPROVED NEW WARNINGS ABOUT INCREASED RISK OF BLOOD CLOTS & OF DEATH WITH THE 10 MG TWICE DAILY DOSE OF TOFACITINIB (XELJANZ, XELJANZ XR).U.S. FDA SAYS THE 10 MG TWICE DAILY DOSE OF TOFACITINIB IS NOT APPROVED FOR RA OR PSORIATIC ARTHRITIS (PSA)..  Full Article

Rising Pharmaceuticals Announces The U.S. Launch Of A Generic Version Of Pregabalin Capsules
Saturday, 20 Jul 2019 

July 19 (Reuters) - Rising Pharmaceuticals::RISING PHARMACEUTICALS - ANNOUNCED U.S. LAUNCH OF GENERIC VERSION OF LYRICA, (PREGABALIN) CAPSULES, IN ALL 8 COMMERCIALLY AVAILABLE STRENGTHS.  Full Article

Health Canada Says Pfizer Confirms EpiPen 0.3 Mg Supply Is Currently Available And Continues To Be Shipped
Friday, 19 Jul 2019 

July 19 (Reuters) - Health Canada::HEALTH CANADA - PFIZER HAS CONFIRMED THAT EPIPEN 0.3 MG SUPPLY IS CURRENTLY AVAILABLE AND CONTINUES TO BE SHIPPED.HEALTH CANADA - PFIZER IS REPORTING THAT IT ESTIMATES EPIPEN 0.3 MG SUPPLY ISSUE WILL BE FULLY RESOLVED IN EARLY OCTOBER 2019.HEALTH CANADA - PFIZER INDICATED THAT IT HAS BEGUN MANAGING DISTRIBUTION OF EXISTING EPIPEN 0.3 MG SUPPLY TO HELP ENSURE CONSISTENT ACCESS BY PATIENTS.  Full Article

Statement From Health Canada On The Supply Of EpiPen 0.3 Mg Auto-Injectors
Friday, 19 Jul 2019 

July 19 (Reuters) - Health Canada::STATEMENT FROM HEALTH CANADA ON THE SUPPLY OF EPIPEN 0.3 MG AUTO-INJECTORS.HEALTH CANADA - EPIPEN JR (0.15 MG) IS NOT AFFECTED BY SHORTAGE.HEALTH CANADA - AWARE THAT PFIZER CANADA IS REPORTING THAT A SHORTAGE OF 0.3 MG FORMAT EPIPEN AUTO-INJECTOR MAY LEAD TO TEMPORARY SUPPLY CONSTRAINTS.HEALTH CANADA - ANTICIPATES THERE WILL BE ADEQUATE SUPPLY OF EPINEPHRINE AUTO-INJECTORS IN CANADA TO MEET NEEDS OF CANADIANS OVER COMING MONTHS.HEALTH CANADA - INTERIM ORDER THAT FACILITATES IMPORT OF AN ALTERNATIVE EPINEPHRINE AUTO-INJECTOR, AUVI-Q, REMAINS IN EFFECT.HEALTH CANADA - AUVI-Q REMAINS AVAILABLE FOR CANADIANS TO ACCESS.HEALTH CANADA - PFIZER REPORTED SHORTAGE ON JULY 16, INFORMED HEALTH CANADA THAT IT CONTINUES TO SHIP PRODUCT TO CANADA.  Full Article

Calithera Biosciences Initiates Phase 1/2 Trial Of Telaglenastat
Tuesday, 2 Jul 2019 

July 2 (Reuters) - Calithera Biosciences Inc ::CALITHERA BIOSCIENCES INITIATES PHASE 1/2 TRIAL OF TELAGLENASTAT IN COMBINATION WITH PFIZER’S CDK4/6 INHIBITOR PALBOCICLIB.CALITHERA BIOSCIENCES - ANNOUNCED TREATMENT OF FIRST PATIENT IN PHASE 1/2 TRIAL OF GLUTAMINASE INHIBITOR TELAGLENASTAT WITH PFIZER'S IBRANCE.CALITHERA BIOSCIENCES INC - AS PART OF AGREEMENT, PFIZER IS PROVIDING PALBOCICLIB AND TALAZOPARIB, AS WELL AS FINANCIAL SUPPORT.  Full Article

Purdue OxyContin settlement would rank among largest in pharma history

OxyContin maker Purdue Pharma LP has reached a tentative multibillion-dollar agreement with some plaintiffs aimed at settling thousands of lawsuits over its alleged role in the U.S. opioid crisis, Reuters reported on Wednesday, citing people familiar with the matter.